Making Medicine

Incubate Coalition

There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

  1. قبل ٤ أيام

    What the NDAA Means for the Future of Biotech

    This episode breaks down how Congress is turning biotechnology into a core national security priority. John Stanford explains the biggest shifts in the 2025 defense bill, why China-focused guardrails are expanding, and how new investment rules could reshape biotech funding. We also cover a new bipartisan proposal to create a government-backed investment fund, and a high-stakes battle over ACA subsidies. What NDAA change do you think will impact biotech most? Should the U.S. invest directly in emerging biotechnologies? How should policymakers balance security with scientific innovation?   If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true   Timestamps: 0:00 Disclaimers & Intro 0:23 NDAA Overview and Why It Matters 1:54 Biotech as a Strategic National Security Capability 2:54 Domestic Biomanufacturing & Supply Chain Priorities 3:19 DoD Bioindustrial Base & New Biotech Office 4:34 Data Standardization, AI Readiness & Security 5:07 Guarding the U.S. Biotech Ecosystem from China 7:09 Intelligence Community’s New Biotech Role 8:00 Outbound Investment Regime Explained 10:12 Implications for Investors & Biotech Leaders 12:42 The Independence Investment Fund Act 14:37 Why Congress Wants a Government-Backed Biotech Fund 14:40 Senate Showdown on ACA Subsidies & Healthcare Costs 17:36 Why Access and Innovation Are Interconnected 18:17 Closing Thoughts & Call for Questions DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

    ١٩ من الدقائق

  2. ٤ ديسمبر

    Inside Congress: Senator Thom Tillis on Drug Pricing, IP, and the Future of Innovation

    In this episode of Making Medicine, host John Stanford sits down with Senator Thom Tillis, the first sitting U.S. Senator to join the show. Tillis opens up about his relationship with President Trump, the impact of Most Favored Nation (MFN) drug pricing on U.S. innovation, and the forces shaping America’s biotech competitiveness. They discuss why predictable intellectual property and regulatory frameworks are critical for investment and how the U.S. can maintain a leading edge in life sciences. Don’t miss Tillis’s insights on why he chose not to seek reelection and what might come next for his career. This is a must-listen for anyone interested in biotech policy, life sciences innovation, or U.S. global competitiveness. What do you think about MFN-style pricing in the U.S.? How can policymakers best support biotech innovation? Which part of the life sciences ecosystem do you think needs the most attention right now? If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Timestamps: 0:00 Introduction to Making Medicine and Senator Thom Tillis 1:12 Tillis joins the podcast as the first sitting Senator 2:05 Early career and motivations in public service 4:20 Relationship with President Trump and MFN drug pricing 7:35 Potential impacts of MFN-style controls on U.S. innovation  10:10 America’s global biotech competitiveness and China 13:50 Importance of IP and regulatory predictability for investment 16:25 Reflections on policy successes and challenges 18:40 Decision not to seek reelection 20:30 What’s next for Senator Tillis 22:00 Key takeaways on biotech policy and U.S. innovation 24:15 Closing thoughts and call to action DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

    ٢٩ من الدقائق

  3. ٢٥ نوفمبر

    Making Medicine ft. Daphne Zohar. Biotech Flywheels, Policy Risks, and the Future of Innovation

    In this episode of the Making Medicine Podcast, John Stanford sits down with Daphne Zohar, Founder, CEO, and Board Member of Seaport Therapeutics to explore the forces shaping today’s biotech ecosystem. Daphne shares her entrepreneurial path from PureTech to Seaport, offering a rare inside look at building companies, catalyzing innovation, and scaling breakthrough science. The conversation dives into the Massachusetts biotech flywheel, competitiveness with China, U.S. policy risks like the pill penalty and MFN, and how regulatory uncertainty ripples through capital formation and patient impact. Daphne also highlights why she’s bullish heading into 2026 and offers tactical advice for founders gearing up for JPM.   What part of Daphne’s perspective resonated most with you? Which policy issue do you believe will most affect biotech innovation in 2025? What should we ask her next time she joins the show? If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Timestamps: 0:00 Welcome & Introduction 1:12 Daphne Zohar’s Path into Biotech 3:05 The Seaport Therapeutics Story 6:10 Biotech Hangout & CEO Sisterhood 8:42 Why Massachusetts Leads in Biotech 10:55 The M&A Flywheel & Metsera Deal 13:40 China’s Biotech Strategy & U.S. Competitiveness 16:20 Pill Penalty, EPIC Act & Drug-Pricing Distortions 18:55 MFN Proposals & Impact on Early-Stage Biotechs 21:30 FDA Uncertainty: Regulation, Capital & Patients 24:00 Positive Signals Heading Into 2026 26:15 JPM Outlook & Advice for Founders DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

    ٣٧ من الدقائق

  4. ٢٠ نوفمبر

    Japan’s Life Sciences State of Play: The Takeaways You Can’t Miss

    In this special Tokyo edition of the Making Medicine Podcast, John Stanford hosts a powerhouse panel of biotech investors, founders, and industry leaders to break down Japan’s emerging life-sciences boom. Together, they explore Japan’s regulatory shifts, government incentives, and rising startup momentum. This episode unpacks how Japan is positioning itself as a global hub for regenerative medicine, gene therapy, and bioeconomy innovation. Whether you're a policymaker, entrepreneur, or simply curious about global biotech trends, you'll get a front-row seat to Japan’s life sciences ecosystem, and why the rest of the world is watching. What part of Japan’s biotech ecosystem surprised you the most? Do you think global biotech companies should be paying more attention to Japan? Why or why not? Where do you see the biggest opportunity for Japan to lead in biotech? If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Time Stamps: 0:00 Introduction: Why We’re Recording in Tokyo 2:45 Japan’s Biotech Vision: From Strategy to Reality 6:10 Role of Government & Public-Private Partnerships 9:20 Innovation Hubs: Shared Labs & Incubators 12:05 Investment Landscape: VCs, Funds & Incentives 15:30 Regenerative Medicine & iPSC Development 18:45 Gene & Cell Therapy Trends in Japan 22:00 Regulatory Reform & Drug Approval Acceleration 24:45 Global Biotech Partnerships: Japan’s Reach Abroad 27:10 Challenges: From Risk-Averse Culture to Commercialization 29:50 The Bioeconomy: Beyond Pharmaceuticals 32:15 What’s Next: Predictions for Japan’s Biotech Future DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

    ٤٠ من الدقائق

  5. ١٣ نوفمبر

    Inside Biotech Leadership: Bill Newell on Innovation, Capital, and Policy at Sutro Biopharma

    Former Sutro Biopharma CEO Bill Newell joins host John Stanford to discuss the realities of leading a biotech company through economic uncertainty, long development timelines, and a shifting policy landscape. Bill shares lessons from 16 years at the helm, raising over $1.6 billion, navigating clinical trials, and building partnerships with global pharma leaders. The episode dives deep into the challenges of price controls, intellectual property reform, and the importance of FDA consistency for innovation. A must-watch for anyone interested in how science, policy, and investment intersect to bring new medicines to life. What surprised you most about the biotech development process? How do you think policymakers should balance access and innovation? Do you agree with Bill’s stance on price controls and IP reform? If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

    ٢٨ من الدقائق

  6. ٦ نوفمبر

    U.S. Biomanufacturing Surge, Arena BioWorks Fallout & GLP-1 Rumors | Making Medicine Podcast

    In this episode, John Stanford breaks down the surge in U.S. biomanufacturing investments, including Virginia’s new $500B hub, and what it means for the nation’s workforce. He contrasts this expansion with the recent closure of Arena BioWorks, raising questions about the balance between onshoring and sustaining innovation. The discussion also dives into major rumors of a potential Medicare-GLP-1 deal with Eli Lilly and Novo Nordisk and explores the possible implications of new CMS demonstration projects that could impact Part B manufacturers. Finally, John reflects on the growing pressure of tax and pricing policies that could reshape the biotech landscape. Do you think the U.S. is striking the right balance between manufacturing and innovation? How might Medicare coverage of GLP-1 drugs change the healthcare system? What policy signals should Congress send to protect early-stage biotech? If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true 0:00 Disclaimer and introduction 0:23 Welcome to the Making Medicine Podcast 0:57 FDA leadership shakeup and industry uncertainty 2:06 Arena BioWorks closure and policy contrasts 2:32 FDA predictability and regulatory challenges 3:28 Medicare and GLP-1 coverage discussion 4:08 New FDA guidance on biosimilars and gene editing 5:00 FDA moves to reduce biosimilar development costs 5:49 Gene editing progress and regulatory flexibility 6:53 Impact of pricing and revenue policies on innovation 7:48 Arena BioWorks shutdown and biotech investment climate 10:40 Virginia’s new manufacturing hub and workforce initiative 13:14 White House drug pricing rumors and CMMI demonstration projects 17:39 Closing thoughts and call for engagement  DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

    ١٨ من الدقائق

  7. ٣٠ أكتوبر

    Is the U.S. Losing Its Biotech Edge to China? Senate Hearing & Innovation Outlook

    In this episode of Making Medicine, host John Stanford unpacks the Senate HELP Committee hearing on “The Future of Biotech.” From China’s accelerating investment to U.S. policy uncertainty, he explores what’s needed to protect American leadership in life sciences. The episode also covers new White House biosimilar announcements, gene therapy market challenges, and early insights from Incubate Policy Lab’s investment analysis. With over $14 billion invested in early-stage biotech this year, the conversation turns to what’s next for U.S. innovation. Do you think U.S. biotech can stay ahead of China? What policies would best support innovation?  Should biosimilars have faster, simpler approvals?If you're new to the  Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true Timestamps: 0:00 – Intro and disclaimer 0:23 – Senate hearing: “The Future of Biotech” overview 1:19 – China’s biotech rise and U.S. competitiveness concerns 2:10 – IP protection, FDA modernization, and investment flight 3:30 – NIH funding stability and bipartisan support 4:00 – PBM reform and patient access challenges 6:00 – John Crowley’s warning: U.S. could lose biotech leadership in 2–3 years 8:00 – Incubate Policy Lab report: “Red lights in the U.S., green lights in China” 10:00 – Policy solutions: pricing predictability and IP certainty 12:00 – White House biosimilars announcement explained 14:00 – Gene and cell therapy market struggles 15:30 – AI-driven biotech investments and top-performing states 17:00 – Incubate at JPM 2026 + FDA during government shutdown 18:12 – Closing thoughts and audience shout-outsDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

    ١٩ من الدقائق

  8. ٢٣ أكتوبر

    FDA Vouchers, Orphan Cures & IP with Joshua Kresh

    In this week’s episode, John breaks down the White House headlines, the FDA’s new wave of priority review vouchers, and September approvals, then celebrates National IP Month with guest Joshua Kresh. We dig into criteria for the new wave of CNPVs, domestic manufacturing pushes (Augmentin XR and ketamine), and why some approvals matter for patients who’ve run out of options. John also unpacks the Orphan Cures Act debate, the latest CBO chatter, and what it all means for long-term innovation. Finally, Joshua explains why IP is the backbone of biotech and flags fixes on eligibility, injunctions, and PTAB. Tell us what you think and we may feature your comment next week. What’s your take on the FDA’s new voucher selections - smart acceleration or risky subjectivity?  Should Congress protect the Orphan Cures Act or revisit it in light of CBO’s estimates? If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: https://x.com/MakingMedPod https://www.instagram.com/makingmedicinepod/ https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true  Timestamps: 0:00 Disclaimers 0:23 Welcome & episode setup 0:46 Headlines: White House update & FDA Vouhcer program 1:20 FDA criteria & first recipients (overview) 3:00 Domestic manufacturing: Augmentin XR & ketamine 3:55 Approvals Corner: September FDA approvals 4:54 Orphan Cures Act: fix, CBO score & repeal talk 6:49 Tracking investor sentiment: life science & rare disease 8:05 National IP Month intro 8:47 Guest Joshua Kresh & IPI’s mission 12:36 The big IP issues: eligibility, injunctions (RESTORE), PTAB 24:49 Outro & call to action DISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

    ٢٥ من الدقائق
مشاهدة الكل (٥٥)

مقطع ترويجي

التقييمات والمراجعات

٥
من ٥
‫١٥ من التقييمات‬

حول

There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

المعلومات

  • صناع العمل
    Incubate Coalition
  • سنوات النشاط
    ٢٠٢١ - ٢٠٢٥
  • الحلقات
    ٥٥
  • التقييم
    ملائم
  • حقوق النشر
    © Copyright Sweet Fish
  • موقع البرنامج على الويب
    Making Medicine

قد يعجبك أيضًا